Clinical Trial Update: Phase III Study on HMPL-523 for Treatment of ITP [Phase 3]

View source ↗

Summary

Phase III study of HMPL-523 for Primary Immune Thrombocytopenia is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• HMPL-523

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Primary Immune Thrombocytopenia (ITP) | Phase 3 | Status: ACTIVE_NOT_RECRUITING